We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues 2024 Priorities for CDER Guidances, BsUFA Research Roadmap
FDA Issues 2024 Priorities for CDER Guidances, BsUFA Research Roadmap
The FDA has issued a revised version of its Biosimilar User Fee Amendment (BsUFA) Research Roadmap and a list of guidances CBER plans to issue during 2024, both intended to clarify the agency’s priorities for 2024.